NCT01121120

Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients

Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (actual)
• Sponsor: Tarix Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety and effectiveness of TXA127 in accelerating the time it takes for patients to recover their platelet counts following a Autologous Peripheral Blood Stem Cell transplant.

Detailed description

* This is a randomized, double-blind (Investigator and Study Subject), placebo-controlled study. * The conditioning regimen and mobilization agents used will be up to the discretion of the Study Center Investigator

Conditions

• Lymphoma, Non-Hodgkin
• Hodgkin Disease
• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	TXA127	300mcg/kg/day, administered subcutaneously for up to 28 days
DRUG	Placebo	300mcg/kg/day administered subcutaneously for up to 28 days

Timeline

• Start date: 2010-06-01
• Primary completion: 2020-12-01
• Completion: 2020-12-01
• First posted: 2010-05-12
• Last updated: 2020-12-08

Locations

10 sites across 1 country: United States